Saturday, April 29, 2017 12:56:00 PM
Look up his history with Allergan and $VRX. He doesn't like getting taken out, and especially not buy bad people.
I don't see him taking to kind to a buy out unless it is at a premium to what he paid. although, Lykos and a few others are still the majority holders. I think it is more likely that one of the big boys (ZYNE, GW, INSYS) hit it big, and other banks start looking at the space more serious. More eyes on the sector, and NMUS will be able to get serious funding for their candidates.
Until then, were in survival mode while the company continues to do the little things right.
Capital is not going to be as efficient on the OTC as other markets. Patience will rewards us well with NMUS I think.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM